These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 29412124)

  • 41. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
    Kumar S; Khatik GL; Mittal A
    Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis.
    Iketani R; Imai S
    Biol Pharm Bull; 2023; 46(4):592-598. PubMed ID: 37005303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meta-analysis of the effect of sodium-dependent glucose transporter 2 inhibitors on C-reactive protein in type 2 diabetes.
    Sun W; Xing Y; Kong D; Zhang Z; Ma H; Yang L
    Medicine (Baltimore); 2022 Sep; 101(38):e30553. PubMed ID: 36197267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
    Stavropoulos K; Imprialos KP; Stavropoulos N; Bouloukou S; Kerpiniotis G; Dimitriadis K; Tsioufis C; Doumas M
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):120-126. PubMed ID: 29412122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus.
    Griffin TP; Islam MN; Blake L; Bell M; Griffin MD; O'Shea PM
    Horm Metab Res; 2019 Feb; 51(2):91-99. PubMed ID: 30522145
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
    Langford BE; Evans M; Haskins-Coulter T; O'Connor M; Cant HEO; Eddowes LA; Edmonds C; Tank A
    Diabetes Obes Metab; 2020 Jan; 22(1):39-50. PubMed ID: 31468649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(3):409-18. PubMed ID: 26732230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
    Akbari A; Rafiee M; Sathyapalan T; Sahebkar A
    J Diabetes Res; 2022; 2022():7520632. PubMed ID: 35224108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
    Kosiborod M; Birkeland KI; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Jørgensen ME; Wittbrodt ET; Thuresson M; Bodegård J; Hammar N; Fenici P;
    Diabetes Obes Metab; 2018 Aug; 20(8):1983-1987. PubMed ID: 29569378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes.
    Chilton RJ
    Diabetes Obes Metab; 2020 Jan; 22(1):16-29. PubMed ID: 31407866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Nat Rev Endocrinol; 2020 Oct; 16(10):556-577. PubMed ID: 32855502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?
    Berkovic MC; Bilic-Curcic I; Bozek T; Mahecic DH; Majanovic SK; Canecki-Varzic S; Andric J; Marusic S; Mrzljak A
    World J Diabetes; 2020 Nov; 11(11):540-552. PubMed ID: 33269065
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Lupsa BC; Inzucchi SE
    Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes.
    Siegmund T; Ampudia-Blasco FJ; Schnell O
    Diabetes Res Clin Pract; 2020 Apr; 162():108131. PubMed ID: 32234505
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
    Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
    J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?
    Ahmed-Sarwar N; Nagel AK; Leistman S; Heacock K
    Ann Pharmacother; 2017 Sep; 51(9):791-796. PubMed ID: 28535688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.